Search

Your search keyword '"Labeyrie C."' showing total 172 results
Start Over Author "Labeyrie C."
172 results on '"Labeyrie C."'

1. Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019)

Author

Adams, D., Cintas, P., Solé, G., Tard, C., Labeyrie, C., Echaniz-Laguna, A., Cauquil, C., Pereon, Y., Magy, L., Morales, R. Juntas, Antoine, J.C., Lagrange, E., Petiot, P., Mallaret, M., Francou, B., Guiochon-Mantel, A., Coste, A., Demarcq, O., Geffroy, C., Famelart, V., Rudant, J, Bartoli, M, Donal, E., Lairez, O., Eicher, J.C., Kharoubi, M., Oghina, S., Trochu, J.N., Inamo, J., Habib, G., Roubille, F., Hagège, A., Morio, F., Cariou, E., Adda, J., Slama, M.S., Charron, P., Algalarrondo, V., Damy, T., and Attarian, S.

Published
2024
Full Text
View/download PDF

7. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI

Author

Brochet, B., Casey, R., Cotton, F., De Sèze, J., Douek, P., Guillemin, F., Laplaud, D., Lebrun-Frenay, C., Mansuy, L., Moreau, T., Olaiz, J., Pelletier, J., Rigaud-Bully, C., Stankoff, B., Vukusic, S., Marignier, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Collongues, N., Lubetzki, C., Vermersch, P., Labauge, P., Defer, G., Cohen, M., Fromont, A., Wiertlewsky, S., Berger, E., Clavelou, P., Audoin, B., Giannesini, C., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Créange, A., Camdessanché, J.-P., Faure, J., Maurousset, A., Patry, I., Hankiewicz, K., Pottier, C., Maubeuge, N., Labeyrie, C., Nifle, C., Ameli, R., Anxionnat, R., Attye, A., Bannier, E., Barillot, C., Ben Salem, D., Boncoeur-Martel, M.-P., Bonneville, F., Boutet, C., Brisset, J.-C., Cervenanski, F., Claise, B., Commowick, O., Constans, J.-M., Dardel, P., Desal, H., Dousset, Vincent, Durand-Dubief, F., Ferre, J.-C., Gerardin, E., Glattard, T., Grand, S., Grenier, T., Guillevin, R., Guttmann, C., Krainik, A., Kremer, S., Lion, S., Menjot de Champfleur, N., Mondot, L., Outteryck, O., Pyatigorskaya, N., Pruvo, J.-P., Rabaste, S., Ranjeva, J.-P., Roch, J.-A., Sadik, J.C., Sappey-Marinier, D., Savatovsky, J., Tanguy, J.-Y., Tourbah, A., Tourdias, T., Roca, P., Colas, L., Tucholka, A., Rubini, P., Cackowski, S., Ding, J., Budzik, J.-F., Renard, F., Doyle, S., Barbier, E.L., Bousaid, I., Lassau, N., and Verclytte, S.

Published
2020
Full Text
View/download PDF

9. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Donzé, C., Papeix, C., Lebrun-Frénay, C., Collongues, N., de Seze, M., Dinh, A., Even, A., Scheiber-Nogueira, C., Bensa, C., Bourre, B., Carra-Dallière, C., Ciron, J., Cohen, M., Guennoc, A.M., Louapre, C., Lebreton, F., Michel, L., Maillart, E., Audoin, B., Ayrignac, X., Bernady, P., Brochet, B., Clavelou, P., Colamarino, R., Declemy, A., de Seze, J., Derache, N., Faucheux, J.-M., Heinzlef, O., Labauge, P., Laplaud, D., Lepage, E., Leray, E., Magy, L., Mathey, G., Mekies, C., Mondain, V., Planque, E., Pelletier, J., Pittion, S., Stankhof, B., Tournaire, P., Thouvenot, E., Vukusic, S., Wiertlevski, S., Zephir, H., Alchaar, H., Androdias, G., Benazet, M., Bensmail, D., Biotti, D., Blanchard-Dauphin, A., Bonnan, M., Boutière, C., Branger, P., Bresch, S., Bru, J.-P., Camdessanché, J.-P., Castel Canal, E., Coustans, M., Casez, O., Castan, B., Creange, A., Creisson, E., De Broucker, T., Depaz, R., Douay, X., Dulau, C., Durand-Dubief, F., Fagniez, O., Faucher, M., Floch, A., Fournier, M., Fromont, A., Gallien, P., Gamé, X., Gault, D., Gayou, A., Giroux, M., Gout, O., Grimaud, J., Hautecoeur, P., Kerbrat, A., Kremer, L., Kwiatkowski, A., Labeyrie, C., Lachaud, S., Lanctin-Garcia, C., Lanotte, L., Manchon, E., Maurousset, A., Milor, A.-M., Moisset, X., Mont-Cuquet, A., Moreau, T., Ouallet, J.-C., Patry, I., Peaureaux, D., Pouget, M.-C., Pourcher Martinez, V., Radot, C., Ruet, A., Saint-Val, C., Salmon, A., Taithe, F., Tatevin, P., Vaillant, M., Stahl, J.-P., Vuoto, F., Zaenker, C., and Lebrun-Frenay, C.

Published
2020
Full Text
View/download PDF

11. Evaluating the current physicians’ knowledge and patients’ pathways for diagnosing transthyretin cardiac amyloidosis (ATTR-CM) in France: An extensive survey of diverse medical specialists

Author

Oghina, S., primary, Legallois, D., additional, Fournier, P., additional, Amara, W., additional, Sabouret, P., additional, Piriou, N., additional, Tresorier, R., additional, Andres, E., additional, Bardin, T., additional, Guignard, S., additional, Hyafil, F., additional, Labeyrie, C., additional, Toulza, O., additional, Walle, M., additional, Bouquillon, B., additional, Sauvage, C., additional, Canali, G., additional, Dubois, M., additional, Charron, P., additional, and Damy, T., additional

Published
2024
Full Text
View/download PDF

13. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Abadie, V., Achour, C., Ader, F., Alchaar, H., Alkhedr, A., Andreux, F., Androdias, G., Arjmand, R., Audoin, B., Audry, D., Aufauvre, D., Autreaux, C., Ayrignac, X., Bailbe, M., Benazet, M., Bensa, C., Bensmail, D., Berger, E., Bernady, P., Bertagna, Y., Biotti, D., Blanchard-Dauphin, A., Bonenfant, J., Bonnan, M., Bonnemain, B., Borgel, F., Botelho-Nevers, E., Boucly, S., Bourre, B., Boutière, C., Branger, P., Brassat, D., Bresch, S., Breuil, V., Brochet, B., Brugeilles, H., Bugnon, P., Cabre, P., Camdessanché, J.-P., Carra-Dalière, C., Casez, O., Chamouard, J.-M., Chassande, B., Chataignier, P., Chbicheb, M., Chenet, A., Ciron, J., Clavelou, P., Cohen, M., Colamarino, R., Collongues, N., Coman, I., Corail, P.-R., Courtois, S., Coustans, M., Creange, A., Creisson, E., Daluzeau, N., Davenas, C., De Seze, J., Debouverie, M., Depaz, R., Derache, N., Divio, L., Douay, X., Dulau, C., Durand-Dubief, F., Edan, G., Elias, Z., Fagniez, O., Faucher, M., Faucheux, J.-M., Fournier, M., Gagneux-Brunon, A., Gaida, P., Galli, P., Gallien, P., Gaudelus, J., Gault, D., Gayou, A., Genevray, M., Gentil, A., Gere, J., Gignoux, L., Giroux, M., Givron, P., Gout, O., Grimaud, J., Guennoc, A.-M., Hadhoum, N., Hautecoeur, P., Heinzlef, O., Jaeger, M., Jeannin, S., Kremer, L., Kwiatkowski, A., Labauge, P., Labeyrie, C., Lachaud, S., Laffont, I., Lanctin-Garcia, C., Lannoy, J., Lanotte, L., Laplaud, D., Latombe, D., Lauxerois, M., Le Page, E., Lebrun-Frenay, C., Lejeune, P., Lejoyeux, P., Lemonnier, B., Leray, E., Loche, C.-M., Louapre, C., Lubetzki, C., Maarouf, A., Mada, B., Magy, L., Maillart, E., Manchon, E., Marignier, R., Marque, P., Mathey, G., Maurousset, A., Mekies, C., Merienne, M., Michel, L., Milor, A.-M., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Moussa, M., Naudillon, J.-P., Normand, M., Olive, P., Ouallet, J.-C., Outteryck, O., Pacault, C., Papeix, C., Patry, I., Peaureaux, D., Pelletier, J., Pichon, B., Pittion, S., Planque, E., Pouget, M.-C., Pourcher, V., Radot, C., Robert, I., Rocher, F., Ruet, A., Saint-Val, C., Salle, J.-Y., Salmon, A., Sartori, E., Schaeffer, S., Stankhof, B., Taithe, F., Thouvenot, E., Tizon, C., Tourbah, A., Tourniaire, P., Vaillant, M., Vermersch, P., Vidil, S., Wahab, A., Warter, M.-H., Wiertlewski, S., Wiplosz, B., Wittwer, B., Zaenker, C., Zephir, H., Lebrun, C., and Vukusic, S.

Published
2019
Full Text
View/download PDF

14. Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease.

Author

Bourdin, V., Fossé, Q., Lambotte, O., Joly, B., Coppo, P., Anguel, N., and Labeyrie, C.

Subjects
THROMBOTIC thrombocytopenic purpura, AUTOIMMUNE diseases, DISEASE remission, MONOCLONAL antibodies, DIAGNOSIS, ALEMTUZUMAB
Abstract

Summary: Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life‐threatening disease that may result from drug exposure. We report a case of iTTP occurring in a 39‐year‐old patient, 45 months following introduction of the anti‐CD52 lymphoid cell depleting monoclonal antibody alemtuzumab, to treat a relapsing‐remitting multiple sclerosis. Treatment consisted in plasma exchange, corticosteroids and caplacizumab, allowing clinical remission 3 months after the diagnosis, attested by the absence of thrombocytopenia and recovery of ADAMTS‐13 activity. As other autoimmune disorders, iTTP may occur following alemtuzumab. This diagnosis should be suspected in patients with features of thrombotic microangiopathy following this treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Strategy for genetic analysis in hereditary neuropathy

Author

Masingue, M., primary, Fernández-Eulate, G., additional, Debs, R., additional, Tard, C., additional, Labeyrie, C., additional, Leonard-Louis, S., additional, Dhaenens, C.-M., additional, Masson, M.A., additional, Latour, P., additional, and Stojkovic, T., additional

Published
2023
Full Text
View/download PDF

23. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Author

Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E.K., Debouverie M., Patti F., De Seze J., Izquierdo G., Eichau S., Edan G., Prat A., Girard M., Ozakbas S., Grammond P., Zephir H., Ciron J., Maillart E., Moreau T., Amato M.P., Labauge P., Alroughani R., Buzzard K., Skibina O., Terzi M., Laplaud D.A., Berger E., Grand'Maison F., Lebrun-Frenay C., Cartechini E., Boz C., Lechner-Scott J., Clavelou P., Stankoff B., Prevost J., Kappos L., Pelletier J., Shaygannejad V., Yamout B.I., Khoury S.J., Gerlach O., Spitaleri D.L.A., Van Pesch V., Gout O., Turkoglu R., Heinzlef O., Thouvenot E., McCombe P.A., Soysal A., Bourre B., Slee M., Castillo-Trivino T., Bakchine S., Ampapa R., Butler E.G., Wahab A., Macdonell R.A., Aguera-Morales E., Cabre P., Ben N.H., Van der Walt A., Laureys G., Van Hijfte L., Ramo-Tello C.M., Maubeuge N., Hodgkinson S., Sanchez-Menoyo J.L., Barnett M.H., Labeyrie C., Vucic S., Sidhom Y., Gouider R., Csepany T., Sotoca J., de Gans K., Al-Asmi A., Fragoso Y.D., Vukusic S., Butzkueven H., Kalincik T., Roos I., Malpas C., Leray E., Casey R., Horakova D., Havrdova E.K., Debouverie M., Patti F., De Seze J., Izquierdo G., Eichau S., Edan G., Prat A., Girard M., Ozakbas S., Grammond P., Zephir H., Ciron J., Maillart E., Moreau T., Amato M.P., Labauge P., Alroughani R., Buzzard K., Skibina O., Terzi M., Laplaud D.A., Berger E., Grand'Maison F., Lebrun-Frenay C., Cartechini E., Boz C., Lechner-Scott J., Clavelou P., Stankoff B., Prevost J., Kappos L., Pelletier J., Shaygannejad V., Yamout B.I., Khoury S.J., Gerlach O., Spitaleri D.L.A., Van Pesch V., Gout O., Turkoglu R., Heinzlef O., Thouvenot E., McCombe P.A., Soysal A., Bourre B., Slee M., Castillo-Trivino T., Bakchine S., Ampapa R., Butler E.G., Wahab A., Macdonell R.A., Aguera-Morales E., Cabre P., Ben N.H., Van der Walt A., Laureys G., Van Hijfte L., Ramo-Tello C.M., Maubeuge N., Hodgkinson S., Sanchez-Menoyo J.L., Barnett M.H., Labeyrie C., Vucic S., Sidhom Y., Gouider R., Csepany T., Sotoca J., de Gans K., Al-Asmi A., Fragoso Y.D., Vukusic S., Butzkueven H., and Kalincik T.

Abstract

OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHOD(S): This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12-months were included in the analysis. The primary study outcome was annualised relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULT(S): 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for seven therapies. Annualised rates of relapse (ARR) started to increase 2-months after natalizumab cessation (month 2-4 ARR, 95% confidence interval): 0.47, 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89), and stabilised faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01-0.29). Magnitude of disease reactivation for other therapies was low, but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were higher relapse rate in the year before cessation, female sex, younger age and higher EDSS. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95%CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). CONCLUSION(S): The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different t

Published
2022

24. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Author

Roos, I, Malpas, C, Leray, E, Casey, R, Horakova, D, Havrdova, EK, Debouverie, M, Patti, F, De Seze, J, Izquierdo, G, Eichau, S, Edan, G, Prat, A, Girard, M, Ozakbas, S, Grammond, P, Zephir, H, Ciron, J, Maillart, E, Moreau, T, Amato, MP, Labauge, P, Alroughani, R, Buzzard, K, Skibina, O, Terzi, M, Laplaud, DA, Berger, E, Grand'Maison, F, Lebrun-Frenay, C, Cartechini, E, Boz, C, Lechner-Scott, J, Clavelou, P, Stankoff, B, Prevost, J, Kappos, L, Pelletier, J, Shaygannejad, V, Yamout, B, Khoury, SJ, Gerlach, O, Spitaleri, DLA, Van Pesch, V, Gout, O, Turkoglu, R, Heinzlef, O, Thouvenot, E, McCombe, PA, Soysal, A, Bourre, B, Slee, M, Castillo-Trivino, T, Bakchine, S, Ampapa, R, Butler, EG, Wahab, A, Macdonell, RA, Aguera-Morales, E, Cabre, P, Ben, NH, Van der Walt, A, Laureys, G, Van Hijfte, L, Ramo-Tello, CM, Maubeuge, N, Hodgkinson, S, Sanchez-Menoyo, JL, Barnett, MH, Labeyrie, C, Vucic, S, Sidhom, Y, Gouider, R, Csepany, T, Sotoca, J, de Gans, K, Al-Asmi, A, Fragoso, YD, Vukusic, S, Butzkueven, H, Kalincik, T, Roos, I, Malpas, C, Leray, E, Casey, R, Horakova, D, Havrdova, EK, Debouverie, M, Patti, F, De Seze, J, Izquierdo, G, Eichau, S, Edan, G, Prat, A, Girard, M, Ozakbas, S, Grammond, P, Zephir, H, Ciron, J, Maillart, E, Moreau, T, Amato, MP, Labauge, P, Alroughani, R, Buzzard, K, Skibina, O, Terzi, M, Laplaud, DA, Berger, E, Grand'Maison, F, Lebrun-Frenay, C, Cartechini, E, Boz, C, Lechner-Scott, J, Clavelou, P, Stankoff, B, Prevost, J, Kappos, L, Pelletier, J, Shaygannejad, V, Yamout, B, Khoury, SJ, Gerlach, O, Spitaleri, DLA, Van Pesch, V, Gout, O, Turkoglu, R, Heinzlef, O, Thouvenot, E, McCombe, PA, Soysal, A, Bourre, B, Slee, M, Castillo-Trivino, T, Bakchine, S, Ampapa, R, Butler, EG, Wahab, A, Macdonell, RA, Aguera-Morales, E, Cabre, P, Ben, NH, Van der Walt, A, Laureys, G, Van Hijfte, L, Ramo-Tello, CM, Maubeuge, N, Hodgkinson, S, Sanchez-Menoyo, JL, Barnett, MH, Labeyrie, C, Vucic, S, Sidhom, Y, Gouider, R, Csepany, T, Sotoca, J, de Gans, K, Al-Asmi, A, Fragoso, YD, Vukusic, S, Butzkueven, H, and Kalincik, T

Abstract

BACKGROUND AND OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHODS: This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULTS: A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). DISCUSSION: The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued di

Published
2022

25. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Author

Andersen, JB, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sorensen, PS, Christensen, CCH, Rasmussen, P, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Schreiber, K, Horakova, D, Havrdova, EK, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Maison, FG, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Seze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanche, J-P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M, Andersen, JB, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sorensen, PS, Christensen, CCH, Rasmussen, P, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Schreiber, K, Horakova, D, Havrdova, EK, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Maison, FG, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Seze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanche, J-P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, and Magyari, M

Abstract

BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. METHODS: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. RESULTS: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. CONCLUSION: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.

Published
2021

30. Early detection of cardiac and skin amyloid deposits among asymptomatic carriers of hereditary pathogenic transthyretin mutation

Author

Slama, M., primary, Piekarski, E., additional, Eliahou, L., additional, Beauvais, D., additional, Rouzet, F., additional, Adams, D., additional, Echaniz-Laguna, A., additional, Beaudonnet, G., additional, Cauquil, C., additional, Labeyrie, C., additional, Chong-Nguyen, C., additional, and Algalarrondo, V., additional

Published
2021
Full Text
View/download PDF

31. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI

Author

Roca, P., primary, Attye, A., additional, Colas, L., additional, Tucholka, A., additional, Rubini, P., additional, Cackowski, S., additional, Ding, J., additional, Budzik, J.-F., additional, Renard, F., additional, Doyle, S., additional, Barbier, E.L., additional, Bousaid, I., additional, Casey, R., additional, Vukusic, S., additional, Lassau, N., additional, Verclytte, S., additional, Cotton, F., additional, Brochet, B., additional, De Sèze, J., additional, Douek, P., additional, Guillemin, F., additional, Laplaud, D., additional, Lebrun-Frenay, C., additional, Mansuy, L., additional, Moreau, T., additional, Olaiz, J., additional, Pelletier, J., additional, Rigaud-Bully, C., additional, Stankoff, B., additional, Marignier, R., additional, Debouverie, M., additional, Edan, G., additional, Ciron, J., additional, Ruet, A., additional, Collongues, N., additional, Lubetzki, C., additional, Vermersch, P., additional, Labauge, P., additional, Defer, G., additional, Cohen, M., additional, Fromont, A., additional, Wiertlewsky, S., additional, Berger, E., additional, Clavelou, P., additional, Audoin, B., additional, Giannesini, C., additional, Gout, O., additional, Thouvenot, E., additional, Heinzlef, O., additional, Al-Khedr, A., additional, Bourre, B., additional, Casez, O., additional, Cabre, P., additional, Montcuquet, A., additional, Créange, A., additional, Camdessanché, J.-P., additional, Faure, J., additional, Maurousset, A., additional, Patry, I., additional, Hankiewicz, K., additional, Pottier, C., additional, Maubeuge, N., additional, Labeyrie, C., additional, Nifle, C., additional, Ameli, R., additional, Anxionnat, R., additional, Bannier, E., additional, Barillot, C., additional, Ben Salem, D., additional, Boncoeur-Martel, M.-P., additional, Bonneville, F., additional, Boutet, C., additional, Brisset, J.-C., additional, Cervenanski, F., additional, Claise, B., additional, Commowick, O., additional, Constans, J.-M., additional, Dardel, P., additional, Desal, H., additional, Dousset, Vincent, additional, Durand-Dubief, F., additional, Ferre, J.-C., additional, Gerardin, E., additional, Glattard, T., additional, Grand, S., additional, Grenier, T., additional, Guillevin, R., additional, Guttmann, C., additional, Krainik, A., additional, Kremer, S., additional, Lion, S., additional, Menjot de Champfleur, N., additional, Mondot, L., additional, Outteryck, O., additional, Pyatigorskaya, N., additional, Pruvo, J.-P., additional, Rabaste, S., additional, Ranjeva, J.-P., additional, Roch, J.-A., additional, Sadik, J.C., additional, Sappey-Marinier, D., additional, Savatovsky, J., additional, Tanguy, J.-Y., additional, Tourbah, A., additional, and Tourdias, T., additional

Published
2020
Full Text
View/download PDF

33. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

Author

Brisset, Jean-Christophe, primary, Kremer, Stephane, additional, Hannoun, Salem, additional, Bonneville, Fabrice, additional, Durand-Dubief, Francoise, additional, Tourdias, Thomas, additional, Barillot, Christian, additional, Guttmann, Charles, additional, Vukusic, Sandra, additional, Dousset, Vincent, additional, Cotton, Francois, additional, Ameli, R., additional, Anxionnat, R., additional, Audoin, B., additional, Attye, A., additional, Bannier, E., additional, Barillot, C., additional, Ben Salem, D., additional, Boncoeur-Martel, M.-P., additional, Bonhomme, G., additional, Bonneville, F., additional, Boutet, C., additional, Brisset, J.C., additional, Cervenanski, F., additional, Claise, B., additional, Commowick, O., additional, Constans, J.-M., additional, Cotton, F., additional, Dardel, P., additional, Desal, H., additional, Dousset, V., additional, Durand-Dubief, F., additional, Ferre, J.-C., additional, Gaultier, A., additional, Gerardin, E., additional, Glattard, T., additional, Grand, S., additional, Grenier, T., additional, Guillevin, R., additional, Guttmann, C., additional, Krainik, A., additional, Kremer, S., additional, Lion, S., additional, Champfleur, N. Menjot De, additional, Mondot, L., additional, Outteryck, O., additional, Pyatigorskaya, N., additional, Pruvo, J.-P., additional, Rabaste, S., additional, Ranjeva, J.-P., additional, Roch, J.-A., additional, Sadik, J.-C., additional, Sappey-Marinier, D., additional, Savatovsky, J., additional, Stankoff, B., additional, Tanguy, J.-Y., additional, Tourbah, A., additional, Tourdias, T., additional, Brochet, B., additional, Casey, R., additional, De Sèze, J., additional, Douek, P., additional, Guillemin, F., additional, Laplaud, D., additional, Lebrun-Frenay, C., additional, Mansuy, L., additional, Moreau, T., additional, Olaiz, J., additional, Pelletier, J., additional, Rigaud-Bully, C., additional, Vukusic, S., additional, Debouverie, M., additional, Edan, G., additional, Ciron, J., additional, Lubetzki, C., additional, Vermersch, P., additional, Labauge, P., additional, Defer, G., additional, Berger, E., additional, Clavelou, P., additional, Gout, O., additional, Thouvenot, E., additional, Heinzlef, O., additional, Al-Khedr, A., additional, Bourre, B., additional, Casez, O., additional, Cabre, P., additional, Montcuquet, A., additional, Créange, A., additional, Camdessanché, J.-P., additional, Bakchine, S., additional, Maurousset, A., additional, Patry, I., additional, De Broucker, T., additional, Pottier, C., additional, Neau, J.-P., additional, Labeyrie, C., additional, and Nifle, C., additional

Published
2020
Full Text
View/download PDF

35. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Lebrun, C., primary, Vukusic, S., additional, Abadie, V., additional, Achour, C., additional, Ader, F., additional, Alchaar, H., additional, Alkhedr, A., additional, Andreux, F., additional, Androdias, G., additional, Arjmand, R., additional, Audoin, B., additional, Audry, D., additional, Aufauvre, D., additional, Autreaux, C., additional, Ayrignac, X., additional, Bailbe, M., additional, Benazet, M., additional, Bensa, C., additional, Bensmail, D., additional, Berger, E., additional, Bernady, P., additional, Bertagna, Y., additional, Biotti, D., additional, Blanchard-Dauphin, A., additional, Bonenfant, J., additional, Bonnan, M., additional, Bonnemain, B., additional, Borgel, F., additional, Botelho-Nevers, E., additional, Boucly, S., additional, Bourre, B., additional, Boutière, C., additional, Branger, P., additional, Brassat, D., additional, Bresch, S., additional, Breuil, V., additional, Brochet, B., additional, Brugeilles, H., additional, Bugnon, P., additional, Cabre, P., additional, Camdessanché, J.-P., additional, Carra-Dalière, C., additional, Casez, O., additional, Chamouard, J.-M., additional, Chassande, B., additional, Chataignier, P., additional, Chbicheb, M., additional, Chenet, A., additional, Ciron, J., additional, Clavelou, P., additional, Cohen, M., additional, Colamarino, R., additional, Collongues, N., additional, Coman, I., additional, Corail, P.-R., additional, Courtois, S., additional, Coustans, M., additional, Creange, A., additional, Creisson, E., additional, Daluzeau, N., additional, Davenas, C., additional, De Seze, J., additional, Debouverie, M., additional, Depaz, R., additional, Derache, N., additional, Divio, L., additional, Douay, X., additional, Dulau, C., additional, Durand-Dubief, F., additional, Edan, G., additional, Elias, Z., additional, Fagniez, O., additional, Faucher, M., additional, Faucheux, J.-M., additional, Fournier, M., additional, Gagneux-Brunon, A., additional, Gaida, P., additional, Galli, P., additional, Gallien, P., additional, Gaudelus, J., additional, Gault, D., additional, Gayou, A., additional, Genevray, M., additional, Gentil, A., additional, Gere, J., additional, Gignoux, L., additional, Giroux, M., additional, Givron, P., additional, Gout, O., additional, Grimaud, J., additional, Guennoc, A.-M., additional, Hadhoum, N., additional, Hautecoeur, P., additional, Heinzlef, O., additional, Jaeger, M., additional, Jeannin, S., additional, Kremer, L., additional, Kwiatkowski, A., additional, Labauge, P., additional, Labeyrie, C., additional, Lachaud, S., additional, Laffont, I., additional, Lanctin-Garcia, C., additional, Lannoy, J., additional, Lanotte, L., additional, Laplaud, D., additional, Latombe, D., additional, Lauxerois, M., additional, Le Page, E., additional, Lebrun-Frenay, C., additional, Lejeune, P., additional, Lejoyeux, P., additional, Lemonnier, B., additional, Leray, E., additional, Loche, C.-M., additional, Louapre, C., additional, Lubetzki, C., additional, Maarouf, A., additional, Mada, B., additional, Magy, L., additional, Maillart, E., additional, Manchon, E., additional, Marignier, R., additional, Marque, P., additional, Mathey, G., additional, Maurousset, A., additional, Mekies, C., additional, Merienne, M., additional, Michel, L., additional, Milor, A.-M., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Moussa, M., additional, Naudillon, J.-P., additional, Normand, M., additional, Olive, P., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pacault, C., additional, Papeix, C., additional, Patry, I., additional, Peaureaux, D., additional, Pelletier, J., additional, Pichon, B., additional, Pittion, S., additional, Planque, E., additional, Pouget, M.-C., additional, Pourcher, V., additional, Radot, C., additional, Robert, I., additional, Rocher, F., additional, Ruet, A., additional, Saint-Val, C., additional, Salle, J.-Y., additional, Salmon, A., additional, Sartori, E., additional, Schaeffer, S., additional, Stankhof, B., additional, Taithe, F., additional, Thouvenot, E., additional, Tizon, C., additional, Tourbah, A., additional, Tourniaire, P., additional, Vaillant, M., additional, Vermersch, P., additional, Vidil, S., additional, Wahab, A., additional, Warter, M.-H., additional, Wiertlewski, S., additional, Wiplosz, B., additional, Wittwer, B., additional, Zaenker, C., additional, and Zephir, H., additional

Published
2019
Full Text
View/download PDF

37. Neurological Complications Induced by Anti-PD-1 or Anti-PD-L1: Prevalence, Clinical Description and Treatment: 5-Years Experience of a National Network

Author

Plaçais, Léo, primary, Michot, Jean-Marie, additional, Champiat, Stephane, additional, Romano-Martin, Patricia, additional, Baldini, Capucine, additional, Joao, Maria Silva, additional, Marabelle, Aurelien, additional, Voisin, A. L., additional, Not, A., additional, Labeyrie, C., additional, Beaudonnet, G., additional, Maria, A., additional, Néel, Antoine, additional, Massaud, Agathe, additional, Dehette, Stéphanie, additional, Echaniz-Laguna, Andoni, additional, Denier, Christian, additional, Adams, David, additional, Lambotte, Olivier, additional, Noel, Nicolas, additional, and Cauquil, Cécile, additional

Published
2019
Full Text
View/download PDF

39. Comparison of Lewis–Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre.

Author

Fargeot, G., Maisonobe, T., Psimaras, D., Debs, R., Lenglet, T., Adams, D., Vandendries, C., Labeyrie, C., and Viala, K.

Subjects
TERTIARY care, ARM, MOTOR neuron diseases, SYNDROMES, NEURAL conduction
Abstract

Background and purpose: Whether the Lewis–Sumner syndrome (L‐SS) is a distinct entity from other types of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP‐ot) remains controversial. Method: The clinical/electrophysiological characteristics and long‐term outcomes of 45 L‐SS and 35 CIDP‐ot patients were retrospectively compared. Results: The CIDP‐ot group was composed of 11 patients with a typical CIDP, 17 with a pure sensory form, four with a distal form and three with a pure motor form. In the L‐SS group, asymmetric (P < 0.001) and monomelic involvement (P = 0.04) of the upper limbs (P < 0.001) was significantly more frequent; paucisymptomatic forms (Overall Neuropathy Limitations Scale ≤ 1) were less frequent (P < 0.001); electroneuromyography showed that conduction block in intermediate nerve segments was the main demyelinating feature, with frequent F‐wave abnormalities on nerves without conduction block (44%). Long‐term prognosis was globally poorer in the L‐SS group with more frequent aggravation during treatment (P = 0.02), less frequent treatment withdrawal (P = 0.03) and longer time to achieve successful withdrawal (39 vs. 15 months). Conclusions: Our study suggests that L‐SS patients have a less favourable therapeutic response rate and long‐term outcomes. Rapid differentiation of L‐SS from other forms of CIDP is important in order to anticipate a more complicated disease course management, with from one side the inefficacy or even harmfulness of corticosteroids and from the other side a difficult weaning procedure. A prospective study is necessary to confirm these results. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique

Author

Laplaud, D.-A., primary, Barbin, L., additional, Casey, R., additional, Debouverie, M., additional, Vukusic, S., additional, Labauge, P., additional, Brassat, D., additional, Wiertlewski, S., additional, De Seze, J., additional, Edan, G., additional, Brochet, B., additional, Moreau, T., additional, Berger, E., additional, Clavelou, P., additional, Castelnovo, G., additional, Ciron, J., additional, Pelletier, J., additional, Bourre, B., additional, Lubetzki, C., additional, Al Khedr, A., additional, Vermersch, P., additional, Lebrun-Frenay, C., additional, Defer, G., additional, Tourbah, A., additional, Camdessanche, J.-P., additional, Stankoff, B., additional, Labeyrie, C., additional, Patry, I., additional, Creange, A., additional, Gout, O., additional, Heinzlef, O., additional, Casez, O., additional, Magy, L., additional, Guennoc, A.-M., additional, De Broucker, T., additional, Nifle, C., additional, Dupel-Pottier, C., additional, Leray, E., additional, Rollot, F., additional, and Foucher, Y., additional

Published
2018
Full Text
View/download PDF

48. Diagnostic usefulness of plexus magnetic resonance imaging in chronic inflammatory demyelinating polyradiculopathy without electrodiagnostic criteria of demyelination.

Author

Fargeot, G., Viala, K., Theaudin, M., Labeyrie, M.‐A., Costa, R., Léger, J. M., Adams, D., Vandendries, C., and Labeyrie, C.

Subjects
MAGNETIC resonance imaging
Abstract

Background and purpose: The usefulness of plexus magnetic resonance imaging (MRI) in the diagnosis of chronic inflammatory demyelinating polyradiculopathy (CIDP) without definite European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria is currently unclear. Methods: Data from consecutive patients with clinical manifestations suggesting CIDP, with or without (CIDP‐D and CIDP‐ND, respectively) definite EFNS/PNS electrodiagnostic criteria, and referred for plexus MRI in our imaging centre were retrospectively analysed. An expert committee of neurologists compared the level of suspicion of CIDP in CIDP‐ND patients to the blinded/unblinded MRI findings. Plexus MRI was reviewed by a neuroradiologist blinded to the final diagnosis. Results: In all, 38 patients were assessed with suspected CIDP‐ND [7/38 (18%) probable; 13/38 (34%) possible; 18/38 (47%), no EFNS/PNS electrodiagnostic criteria], plus 10 with CIDP‐D. Thirty‐six of the 38 (95%) fulfilled clinical criteria of CIDP variants, including pure sensory neuropathy in 22/36 (61%). Plexus MRI showed abnormalities in 22/38 (58%) patients including increased nerve signal intensity on T2‐weighted images in 22/22 (100%), nerve enlargement in 20/22 (91%) and contrast enhancement in 8/22 (36%). Plexus MRI enabled the expert committee's final diagnosis to be adjusted in 7/38 (18%) patients, and in conjunction with nerve conduction studies was a supportive criterion to classify 7/24 (29%) patients as definite CIDP. MRI abnormalities were more asymmetrical (P = 0.03) and less diffuse (P = 0.1) in CIDP‐ND than in CIDP‐D. Conclusions: Our observations suggest that plexus MRI makes a valuable contribution to the diagnosis of CIDP‐ND patients. Further studies are needed to investigate inter‐rater reliability of clinical and imaging criteria of CIDP in these patients, and the impact on outcomes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results